Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: TheBusDriver who wrote (11924)	1/22/2003 9:13:15 AM
From: Montana Wildhack	Respond to of 14101

It isn't necessary in my opinion to speculate too much about the impact of the approval and launch in Canada on the price. It's easy to see the stock drifted back to the $1.60 range which it had met in the face of the delisting and necessary selling without news. And just as easy to estimate the impact of the approvable letter in Canada which I hope we can agree is the reason the stock moved to the high 2's and showed signs of wanting to stay there despite awareness of cash needs throughout. I put it to you that on full approval and a launch date announced that is considered reasonable - the stock will move to $3.50 plus and will be wanting to stay in that range at least pending further information. If the FDA approval/approvable letter becomes that further information - it will bring the dynamics of a highly probable patent extension of some period and the opportunity to market this unique product in the NSAID Arthritis pain management area. With an $8 billion opportunity the value added will, I believe it is reasonable to say, be outsize the Canadian impact and in addition to the Canadian impact. Don't I think the Canadian approval is fully priced in? No. Not until full approval and launch are achieved. Wolf